10. References
Adelson, D. and Epstein, L.J.: A study of phenothiazines with male and female chronically ill schizophrenic patients. Journal of Nervous and Mental Diseases 134:543(1962).
Angst, J.; Weis, P.; Grof, P.; Baastrup, P.C. and Schou, M.: Lithium prophylaxis in recurrent affective disorders. British Journal of Psychiatry 116: 604 (1970).
Baastrup, P.C.; Poulsen, J. V.; Schou, M.; Thomsen, K. and Amdisen, A.: Prophylactic lithium. Double-blind discontinuation in manic-depressive and recurrent depressive disorders. lancet 2: 326 (1970).
Baastrup, P.C. and Schou, M.: Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Archives General Psychiatry 16:162 (1967).
Blackwell, B. and Shepherd, M.: Prophylactic lithium: Another therapeutic myth? An examination of the evidence to date. Lancet 1: 968 (1968).
Brodie, H.K.H.; Murphy, D.h.; Goodwin, F.K. and Bunney, W.E. Jr.: Catecholamines and mania: The effect of alphamethylparatyrosine on manic behavior and catecholamine metabolism. Clinical Pharmacology and Therapeutics 12: 218 (1971).
Caffey, EM. Jr.; Diamond, L.S.; Frank, T. V.; Grasberger, J.C.; Herman, L.; Klett, C.J. and Rothstein, C: Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal Chronic Diseases 17: 347(1964).
Caldwell, H.C.; Westlake, W.J.; Connor, S.M. and Flanagan, T.: A pharmacokinetic analysis of lithium carbonate absorption from several formulations in man. Journal of Clinical Pharmacology 11: 349(1971).
Casey, J.F.; Bennett, I.F.; Lindley, C.J.; Hollister, L.E.; Gordon, M.H. and Springer, N.N.: Drug therapy in schizophrenia: A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital and placebo. Archives of General Psychiatry 2: 210(1960a).
Casey, J.F.; Hollister, L.E.; Klett, C.J.; Lasky, J.J. and Caffey, E.M. Jr.: Combined drug therapy of chronic schizophrenics. A controlled evaluation of placebo, dextroamphetamine, imipramine, isocarboxazid, and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 117:997(1961).
Casey, J.F.; Lasky, J.J.; Klett, C.J. and Hollister, L.E.: Treatment of schizophrenic reactions with phenothiazine derivatives: A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine and phenobarbital. American Journal Psychiatry 77 7: (1960b).
Colbum, R. W.; Goodwin, F.K.; Bunney, W.E. Jr. and Davis, J.M.: Effect of lithium on the uptake of noradrenaline by synaptosomes. Nature 215:1395 (1967).
Coppen, A.: Biogenic amines and affective disorders; in Ho and McIsaac Brain Chemistry and Mental Disease p. 123 (PlenumPress, New York 1971).
Coppen, A.; Noguera, R.; Baily, J.; Bums, B.H.; Swani, M.; Hare, E.H.; Gardner, R. and Maags, R.: Prophylactic lithium in affective disorders. Controlled trial. Lancet 2: 275(1971).
Coppen, A.; Shaw, D.M.; Malleson, A. and Costain, R.: Mineral metabolism in mania. British Medical Journal1: 71–75(1966).
Curry, S.H.: Chlorpromazine: Concentrations in plasma, excretion in urine and duration of effect. Proceedings of the Royal Society of Medicine 64: 285(1971).
Curry, S.H.; Marshall, J.H.L.; Davis, J.M. and Janowsky, D.S.: Chlorpromazine plasma levels and effects. Archives of General Psychiatry 22:289 (1970).
Davis, J.M.; Bartlett, E. and Termini, B.A.: Overdosage of psychotropic drugs: A review. Diseases of the Nervous System 29:157–246(1968).
Davis, J.M. and Fann, W.E.: Lithium. Annual Reviews of Pharmacology 11: 285 (1971).
Efron, S.H.; Harris, S.R.; Manian, A.A. and Gaudett, L.D.: Levels of extractable and bound chlorpromazine and some of its metabolites in animals and human plasma (in press 1972).
Engelhardt, D.M.; Rosen, B.; Freedman, N. and Margolis, R.: Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization — a re-evaluation. Archives of General Psychiatry 16: 98–101 (1967).
Fieve, R.R., Platman, S. and Plutchik, R.: The use of lithium in affective disorders. I. Acute endogenous depression. American Journal of Psychiatry 125: 487(1968).
Fry, D.E. and Marks, V.: Value of plasma-lithium monitoring. Lancet 7: 886(1971).
Forrest, IS.; Bolt, A.G. and Serra, M.T.: Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death. Biochemical Pharmacology 17: 2061 (1968).
Forrest, I.S.; Forrest, F.M. and Serra, M.T.: Chlorpromazine retention. American Journal of Psychiatry 126: 271 (1969).
Galbrecht, C.R. and Klett, C.J.: Predicting response to phenothiazines: The right drug for the right patient. Journal of Nervous and Mental Diseases 147: 173–183(1968).
Gershon, S.: Lithium in mania. Clinical Pharmacology and Therapeutics77: 168(1970).
Gershon, E.S.; Dunner, D.L. and Goodwin, F.K.: Towards a biology of the affective disorders. Archives of General Psychiatry 25:1 (1971).
Goldberg, S.C.; Frosch, WA.; Drossman, A.K.; Schooler, N.R. and Johnson, G.F.S.: Prediction of response to phenothiazines in schizophrenia. A cross-validation study. Archives of General Psychiatry 26: 367 (1972).
Goldfield, M. and Weinstein, M.R.: Lithium in pregnancy: A review with recommendations. American Journal of Psychiatry 727: 888 (1971).
Goodwin, F.K.; Brodie, H.K.H.; Murphy, D.L. and Bunney, W.E. Jr.: L-dopa, catecholamines and behavior: A clinical and biochemical study in depressed patients. Biological Psychiatry 2: 341 (1970).
Gorham, D.R. and Pokorny, A.D.: Effects of a phenothiazine and/or group psychotherapy with schizophrenics. Diseases of the Nervous System 25: 77 (1964).
Grinspoon, L.; Ewalt, J.R. and Shader, R.: Long-term treatment of chronic schizophrenia. International Journal of Psychiatry 4: 116(1967).
Hammar, CG.; Holmsteadt, B.; Lindgren, J.E. and Tham, R.: The combination of gas chromatography and mass spectrometry in the identification of drugs and metabolites. Advances in Pharmacology and Chemotherapy 7: 53(1969).
Haskovec, L. and Rysanek, K: Die Wirkung von Lithium auf den Metabolismus der Katecholamine und Indolalkylamine beim Menschen. Arzneimittel Forschung 19: 426(1969).
Heston, L.L.: The genetics of schizophrenic and schizoid disease. Science 167: 249(1970).
Hollister, LE: Complications from psychotherapeutic drugs. Clinical Pharmacology and Therapeutics 5: 322(1964).
Hollister, L.E: Clinical use of psychotherapeutic drugs. Current status. Clinical Pharmacology and Therapeutics 10:170(1969).
Hollister, L.E. and Curry, S.H.: Urinary excretion of chlorpromazine metabolites following single doses and in steady-state conditions. Research Communications in Chemical Pathology and Pharmacology 2: 330 (1971).
Hollister, L.E.; Curry, S.H.; Derr, J.E. and Kanter, S.L.: Studies of delayed-action medication. V. Plasma levels and urinary excretion of chlorpromazine in four different dosage forms given acutely and in steady-state conditions. Clinical Pharmacology and Therapeutics 11: 49(1970).
Hollister, L.E.; Overall, J.E.; Bennett, J.L.; Kimbell, I. Jr. and Shelton, J.: Specific therapeutic actions of acteophenazine, perphenazine and benzquinamide in newly-admitted schizophrenic patients. Clinical Pharmacology and Therapeutics 8:249 ( 1967).
Hullin, R.P.; Swinscoe, J.C.; McDonald, R. and Dransfleld, G.A.: Metabolic balance studies on the effect of lithium salts in manic-depressive psychosis. British Journal of Psychiatry 114: 1561 (1968).
Janssen, P.A.J.: Chemical and pharmacological classification of neuroleptics; in Bobon, Janssen and Bobon Modern Problems in Pharmacopsychiatry: The Neuroleptics, vol 5, p. 34–44 (Karger, Basel 1970).
Johnson, G.; Gershon, S.; Burdock, E.I; Floyd, A. and Hekemian, L: Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. British Journal of Psychiatry 119: 267 (1971).
Kaim, S.C.; Klett, C.J. and Rothfeld, B.: Treatment of the acute alcohol withdrawal state: A comparison of four drugs. American Journal of Psychiatry 125: 1640–1646(1969).
Klett, C.J. and Caffey, E. Jr.: Evaluation of the long-term need for antiparkinson drugs by chronic schizophrenics. Archives of General Psychiatry 26: 374 (1972).
Laskey, J.J.; Klett, C.J.; Caffey, E.M. Jr.; Bennett, J.L.; Rosenblum, M.P. and Hollister, L.E.: Drug treatment of schizophrenic patients: A comparative evaluation of chlorpromazine, chlorprothixene, fluphenazine, reserpine, thioridazine and triflupromazine. Diseases of the Nervous System 23: 698 (1962).
Leemsta, J.E. and Koenig, K.L.: Sudden death and phenothiazines. A current controversy. Archives of General Psychiatry 18: 137(1968).
Leff, J.P. and Wing, J.K.: Trial of maintenance therapy in schizophrenia. British Medical Journal 3: 599 (1971).
Lorr, M. and Klett, J.: Psychotic behavioral types. A crosscultured comparison. Archives of General Psychiatry 20: 592(1969).
Mendels, J.: Relationship between depression and mania. Lancet 1: 342(1971).
Merlis, S.; Sheppard, C.; Collins, L. and Fiorentino, D.: Polypharmacy in psychiatry: Patterns of differential treatment. American Journal of Psychiatry 126: 1647(1970).
Michaux, M.H.; Hanlon, T.E.; Ota K. Y. and Kurland, A.A.: Phenothiazines in the treatment of newly admitted state hospital patients: Global comparison of eight compounds in terms of an outcome index. Current Therapeutic Research 6: 331 (1964).
National Institute of Mental Health-Psychopharmacology Service Center Collaborative Study Group: Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 10: 246 ( 1964).
Orlov, P.; Kasparian, G; Di Mascio, A. and Cole, J.O.: Withdrawal of antiparkinson drugs. Archives of General Psychiatry 25:410 ( 1971).
Overall, J.E; Hollister, LE. and Pichot, P.: Major psychiatric disorders. A four-dimensional model. Archives of General Psychiatry 16: 146 (1967).
Pisciotta, A.V.: Mechanisms of Phenothiazine Induced Agranulocytosis; in Efron Psychopharmacology. A Review of Progress 1957–1967, p. 597–605 (Public Health Service Publication No. 1836, U.S. Government Printing Office, Washington DC 1968).
Piatman, S.; Rorhlich, J. and Fieve, R.: Absorption and excretion of lithium in manic-depressive disease. Diseases of the Nervous System 29: 733(1968).
Platman, S.R.: Lithium and rubidium: A role in the affective disorders. Diseases of the Nervous System 32: 604(1971).
Piatman, S.R. and Fieve, R.R.: Biochemical aspects of lithium in affective disorders. Archives of General Psychiatry 19: 659(1968).
Piatman, S.R.; Hilton, J.G; Koss, M.C. and Kelly, W.G.: Production of cortisol in patients with manicdepressive psychosis treated with lithium carbonate. Diseases of the Nervous System 32: 542 (1971).
Polatin, P. and Fieve, R.R.: Patient rejection of lithium carbonate prophylaxis. Journal of the American Medical Association 218: 864(1971).
Prien, R.F.; Caffey, E.M. Jr. and Klett, C.J.: A comparison of lithium carbonate and chlorpromazine in the treatment of mania. Archives of General Psychiatry 26: 146(1972a).
Prien, R.F.; Caffey, E.M. Jr. and Klett, C.J.: The relationship between serum lithium level and clinical response in acute manics treated with lithium carbonate. British Journal of Psychiatry 120: 409 (1972b).
Prien, R.F. and Cole, J.O.: High dose chlorpromazine therapy in chronic schizophrenia. Report of NIMH-Psychopharmacology Research Branch Collaborative Study Group. Archives of General Psychiatry 18: 482(1968).
Prien, R.F.; De Long, S.L.; Cole, J.O. and Levine, J.: Ocular changes occurring with prolonged high dose chlorpromazine therapy. Archives of General Psychiatry 23: 464(1970).
Ramsey, T.A.; Mendels, J.; Stokes, J.W. and Fitzgerald, R.G.: Lithium carbonate and kidney function. A failure in renal concentrating ability. Journal of the American Medical Association 279: 1446 (1972).
Rifkin, A.; Quitkin, R.; Carrillo, C. and Klein, D.F.: Very high dosage fluphenazine for nonchronic treatmentrefractory patients. Archives of General Psychiatry 25: 398(1971).
Schildkraut, J.J. and Kety, S.S.: Biogenic amines and emotion. Science 156: 21 ( 1967).
Schou, M.: Lithium in psychiatric therapy and prophylaxis. Journal of Psychiatric Research 6: 67 (1968).
Shopsin, B.; Freidmann, R. and Gershon, S.: Lithium and leucocytosis. Clinical Pharmacology and Therapeutics 12: 923 (1971).
Singer, K and Cheng, M.N.: Thiopropazate hydrochloride in persistent dyskinesia. British Medical Journal 4: 22(1971).
Stach, K. and Poldinger, W.: Strukturelle Betrachtungen der Psychopharmaka: Versuch einer Korrelation von chemischer Konstitution und clinischer Wirkung; in Jucker Progress in Drug Research, p. 129–190 (Birkhauser Verlag, Basel 1966).
Stokes, J. W.; Mendels, J.; Secunda, S.K. and Dyson, W.L.: Lithium excretion and therapeutic response. Journal of Nervous and Mental Diseases 154: 43 (1972).
Stokes, P.E.; Stoll, P.M.; Shamoian, C.A. and Patton, M.J.: Efficacy of lithium as acute treatment of manicdepressive illness. Lancet 1: 1319 (1971).
Usdin, E.: The assay of chlorpromazine and metabolites in blood, urine and other tissues. CRC Critical Reviews in Clinical Laboratory Sciences 2: 347(1971).
Van Praag, H.M.; Schut, T.; Dols, L. and Van Schilfgaarden, R.: Controlled trial of penfluridol in acute psychosis. British Medical Journal 4: 710(1971).
Weil-Malherbe, H. and Szara, S.I.: in Thomas The Biochemistry of Functional and Experimental Psychosis p. 53–91 (Springfield, Ill. 1971).
Wilson, J.H.P.; Donker, A.J.M.; Van Der Hem, G.K. and Wientjes, J.: Peritoneal dialysis for lithium poisoning. British Medical Journal 2: 749 ( 1971).
Zall, H.; Therman, P. O. G. and Myers, J.M.: Lithium carbonate: A clinical study. American Journal of Psychiatry 125: 549(1968).
Author information
Authors and Affiliations
Additional information
First of two parts.
Rights and permissions
About this article
Cite this article
Hollister, L.E. Clinical Use of Psychotherapeutic Drugs I: Antipsychotic and Antimanic Drugs. Drugs 4, 321–360 (1972). https://doi.org/10.2165/00003495-197204050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197204050-00001